Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

about

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

Item

http://www.wikidata.org/entity/Q49576059

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

@en

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

@nl

type

Item

label

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

@en

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

@nl

prefLabel

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

@en

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

@nl

P1476

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.

@en

P2093

Brendan J Jenkins

http://www.w3.org/2001/XMLSchema#string

Daniel Croagh

http://www.w3.org/2001/XMLSchema#string

Joanne Lundy

http://www.w3.org/2001/XMLSchema#string

William Berry

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular profiling of patient-derived breast cancer xenografts

Global cancer statistics

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

c-Met as a Target for Personalized Therapy

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

P31

scholarly article

P356

10.3390/CANCERS10020035

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29382047

http://www.w3.org/2001/XMLSchema#string

P932

5836067

http://www.w3.org/2001/XMLSchema#string